According to court documents from the Judicial Panel on Multidistrict Litigation, as of November 16, 2015, there were 2,266 lawsuits consolidated in MDL 2592, before US District Judge Eldon Fallon. That’s up significantly from the 1,698 lawsuits consolidated as of October 15, 2015.
Xarelto, known generically as rivaroxaban, is a newer-generation anticoagulant, used to reduce the risk of blood clots and strokes. It, like other newer anticoagulants, were developed as an alternative to Coumadin (known generically as warfarin), because Coumadin required regular blood monitoring. Because anticoagulants prevent blood clots, however, they are associated with an increased risk of serious bleeding events.
Coumadin has an antidote in the form of vitamin K. Patients who took Coumadin and experienced a serious bleeding event could be given vitamin K and have the anticoagulant effects reversed. Newer-generation anticoagulants, however, were approved for use on the market without an antidote. That means if patients experienced a bleeding event, they would have to wait for the drug to leave their system. Plaintiffs allege if they had known there was no antidote to Xarelto, they would not have used the medication.
The first bellwether Xarelto trials are expected to go to court early in 2017, meaning there is still time for patients who were affected by Xarelto to file lawsuits.
One such lawsuit was filed by Ashlie Fluitt, whose grandmother died while on Xarelto therapy. The patient, Hattie Deville-Goodwin, was prescribed Xarelto in September 2014 to treat deep vein thrombosis. Only two months after she began using Xarelto, Deville-Goodwin experienced an intracranial bleed, which became an “irreversible and fatal bleed.” She died on November 14, 2014, according to court documents.
READ MORE XARELTO LEGAL NEWS
The lawsuit is Fluitt v. Janssen Research & Development, et al, case number 2:15-cv-05874 in the US District Court, Eastern District of Louisiana.